Press releases

Galenica on track with sales growth

Ad hoc announcement pursuant to Art. 53 LR, Thursday, 23 May 2024

The Galenica Group made a good start to the new year with sales growth of 4.8% to CHF 1,255.5 million in the first four months of 2024. All Service Units performed well and contributed to the good sales performance. 

The sales growth is based on a positive development of the pharmaceutical market with growth of 4.0% (IQVIA, Pharmaceutical Market Switzerland, YTD April 2024). Compared to the prior-year period, the first four months of 2024 included an additional day of sales, with an estimated positive impact of around 1% on sales growth. Significantly increased sales of generics and biosimilars dampened growth. This development was driven by the measures for the promotion of generics and biosimilars that entered into force on 1 January 2024, including an increase in the deductible if patients prefer a more expensive original medicine. Galenica pharmacies increased the generic substitution rate from 75.2% at the end of 2023 to 80.5% in the first four months of 2024, thus making a significant contribution to curbing rising healthcare costs.

Galenica continues to grow in the 2023 financial year

Ad hoc announcement pursuant to Art. 53 LR, Tuesday, 12 March 2024

The Galenica Group achieved strong growth with an increase in sales of 4.4% in the 2023 financial year and generated consolidated net sales of CHF 3,746.0 million. Adjusted for the extraordinary sales related to COVID-19 (self-tests, COVID-19 vaccinations and rapid tests) in the prior-year period, growth amounted to a substantial 5.0%. 

Adjusted1 EBIT increased by 0.4% to CHF 191.3 million, despite special factors in the amount of CHF 9.8 million. Without these special factors, adjusted1 EBIT would have increased by 5.5% to CHF 201.1 million. Thanks to this solid result, the Board of Directors will propose to the Annual General Meeting a dividend at the previous year’s level (CHF 2.20 per share). 

Outlook for 2024

Galenica expects sales growth of between 3% and 5% for the 2024 financial year. Galenica expects adjusted1 EBIT to increase by between 8% and 11%. Adjusted for the special factors in the 2023 financial year in the amount of CHF 9.8 million, this results in a stable development of the adjusted1 EBIT margin (ROS) at 5.4%. Galenica strives for strong yet sustainable dividend growth and plans a dividend for 2024 at least at the previous year’s level.

Detailed information in the Annual report 2023: 

Galenica again achieves strong sales growth

Ad hoc announcement pursuant to Art. 53 LR, Thursday, 18 January 2024

Galenica Group sales performed well in 2023, growing by 4.4% to CHF 3,746.0 million. As expected, sales growth of 3.3% in the second half of 2023 was lower than the +5.5% recorded in the first half due to the exceptionally strong comparative period in the second half of 2022, when there was a strong seasonal flu epidemic and COVID-19 infections.

Subscribe to press releases

Galenica Ltd.
Untermattweg 8
3027 Bern